Skip to content


SELECTRA INVESTMENTS SICAV – J. LAMARCK BIOTECH sub-fund aims at benefiting from increasing share prices in the biotechnology sector. The focus is on mature top tier pharmaceutical biotech companies and companies with interesting pipeline of products in development in a single or numerous markets, like Nasdaq or NYSE. The followed investment policy will enable the sub-fund to increase overall return relative to the Nasdaq Biotech Index by active stock selection of companies, offering the most promising technology platform.

To achieve this investment objective, the sub-fund will take long positions in these shares issued mainly by US issuers, and only secondarily by European or Asian issuers. In order to lower overall risk the sub-fund will not invest in derivatives (such as single stock futures, index futures, warrants or options) to meet the sub-fund’s investment objective. The sub-fund may use financial derivative instruments for the purpose of hedging currency risks only.

The sub-fund may invest up to 10% of its total net assets in shares/units of UCITS and/or other UCIs (including UCITS Exchange Traded Funds (ETF)).

View the latest NAV on Fundsquare market infrastructure:


Expand your business efficiently across borders

Get in touch to find out how we can help your organisation grow in a complex world.

Contact us Contact us